Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211062854> ?p ?o ?g. }
Showing items 1 to 35 of
35
with 100 items per page.
- W4211062854 endingPage "322" @default.
- W4211062854 startingPage "303" @default.
- W4211062854 abstract "As has been discussed in other chapters, we have systemic therapies for psoriasis that are quite effective. However all existing systemic therapies have safety and tolerability concerns. Cyclosporine causes hypertension and renal toxicity, which generally limits its use to <1 year (1). Psoralen/ultraviolet A (PUVA) increases the risk of skin cancer with long-term use and is generally not the treatment of choice in patients with type I or II skin who have had more than 200 treatments (1). The most widely used agent, methotrexate, commonly causes asthenia and evidence of hepatotoxicity and, less commonly, bone marrow toxicity and pneumonitis. Chronically it can cause cirrhosis and portal fibrosis in significant numbers of patients (1). Curiously we can find no published reports in which psoriasis area severity index (PASI) endpoints were used to assess the efficacy of psoriasis treated with methotrexate. In a recent study to assess further its mechanism of action we assessed the efficacy, via PASI, of methotrexate in 25 consecutive patients requiring systemic therapy for psoriasis (K. Callis, 2002 Society of Investigative Dermatology, poster #220). In this study, 23 of 25 patients completed the aggressive treatment program starting at 15 mg/week and moving to as much as 30 mg/week over 6 months. A surprise was that although 65% had az50% reduction in PASI, only 26% had az75% reduction and only 3 (13%) achieved z95% reduction. We conclude from this study that methotrexate is less effective than is commonly believed (>70% who tolerate the drug achieving >75% improvement (2)) when assessed in a prospectivefashion using PASI, the current standard of assessment of improvement. Thus, despite having several effective systemic agents for psoriasis there is an unmet need for psoriasis therapies that have long-lasting efficacy and few side effects." @default.
- W4211062854 created "2022-02-13" @default.
- W4211062854 date "2003-03-19" @default.
- W4211062854 modified "2023-09-23" @default.
- W4211062854 title "Alefacept to Treat Psoriasis" @default.
- W4211062854 cites W1986455689 @default.
- W4211062854 doi "https://doi.org/10.1201/b14220-17" @default.
- W4211062854 hasPublicationYear "2003" @default.
- W4211062854 type Work @default.
- W4211062854 citedByCount "0" @default.
- W4211062854 crossrefType "book-chapter" @default.
- W4211062854 hasConcept C16005928 @default.
- W4211062854 hasConcept C2780564577 @default.
- W4211062854 hasConcept C71924100 @default.
- W4211062854 hasConceptScore W4211062854C16005928 @default.
- W4211062854 hasConceptScore W4211062854C2780564577 @default.
- W4211062854 hasConceptScore W4211062854C71924100 @default.
- W4211062854 hasLocation W42110628541 @default.
- W4211062854 hasOpenAccess W4211062854 @default.
- W4211062854 hasPrimaryLocation W42110628541 @default.
- W4211062854 hasRelatedWork W1986850072 @default.
- W4211062854 hasRelatedWork W1988927864 @default.
- W4211062854 hasRelatedWork W2066907069 @default.
- W4211062854 hasRelatedWork W2143052720 @default.
- W4211062854 hasRelatedWork W2311008277 @default.
- W4211062854 hasRelatedWork W2331246794 @default.
- W4211062854 hasRelatedWork W2601256796 @default.
- W4211062854 hasRelatedWork W3089170113 @default.
- W4211062854 hasRelatedWork W4232493685 @default.
- W4211062854 hasRelatedWork W2604215364 @default.
- W4211062854 isParatext "false" @default.
- W4211062854 isRetracted "false" @default.
- W4211062854 workType "book-chapter" @default.